We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.80 | 8.44% | 48.80 | 48.00 | 49.00 | 49.00 | 45.00 | 45.00 | 5,721,464 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.51 | 137.55M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/1/2020 14:16 | YesTalking about peer group valuation, the US biotech like Monopar is coming to the market for capital, valuing the company at 40x price to book, Avacta is trading at less than 1 !! | nordic1958 | |
28/1/2020 13:09 | Yes. And I would imagine Acvacta are now in a better bargaining position for any deals, so we can expect some juicier ones. | milkmonsta | |
28/1/2020 13:06 | Exactly" significant commercial interest ..."The majors will offer license deals etcThe Koreans will come back for more | nordic1958 | |
28/1/2020 12:40 | Yes, exciting times. "significant commercial interest that Avacta’s development programme has already attracted might now multiply still further." | x54v | |
28/1/2020 12:27 | wow Bavencio is a $4bn p.a. peak sales drug ! Big Pharma will be beating a path to AVCT's door now | the stigologist | |
28/1/2020 12:25 | Ceo on Directors talkhttps://www.dire | nordic1958 | |
28/1/2020 12:12 | This will double in no time... get on board.Added loads more at 17+ to bring average down last week. | losses | |
28/1/2020 10:54 | And Phase 1 trial data should lead to a valuation of at least £100m according to finnCap's recent research note. Current mcap only £41m by comparison. "Based on peer group comparisons (Figure 4), first-in-human Phase I trial data should create an asset with a valuation of at least £100m, as it not only creates value for the individual asset but, more importantly, should be seen as validating the pre|CISION therapeutic platform, from which multiple assets can be generated, each with their own intrinsic risk-adjusted values." | x54v | |
28/1/2020 10:38 | Can't see the Phase I posing any problems here... "Avacta’s first pre|CISION prodrug (AVA6000/pro-doxorub | someuwin | |
28/1/2020 09:49 | Finncaps note: Another box ticked. | money multipier | |
28/1/2020 09:25 | plenty of reason to hold onto this one. gl | purple11 | |
28/1/2020 09:23 | that’s the fear, although not really you could argue - that they’ll get taken out long before they can reach the lofty heights. | bumpa33 | |
28/1/2020 09:21 | Amazing!! Glad my portfolio held on to this one, and my ‘advice’ to this bb was correct. | escapetohome | |
28/1/2020 09:18 | Great news. From their slide deck they estimated the market potential for this as $2 billion of sales for each 1% of market share. And today they are another step closer. A long way to go and I suspect they will be taken out long before then however still very encouraging. See slide 13 | pdt | |
28/1/2020 09:13 | lol - he holds stock doesn't he? Price softening now. A few chased the spike on opening. | 2prsimo | |
28/1/2020 09:08 | From the above... "...Transformational potential – if Avacta’s clinical trial is successful, its value could multiply 10–100x, given the potential scale of collaborations. The upside cannot be understated!" | someuwin | |
28/1/2020 08:29 | Back in....back for good this time, hopefully. | cheshire pete | |
28/1/2020 08:11 | "Thar she blows!" | milkmonsta | |
28/1/2020 08:10 | thanx Bumpa :-) | wanobi | |
28/1/2020 08:10 | As confident of (hopeful lol) yesterday. The sub 20p buys are now consigned to history. | milkmonsta | |
28/1/2020 08:09 | Wan, I don’t trust the fella on their desk, so I’ll check back in an hour or so. | bumpa33 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions